Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Possibly Marketed Outside US

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Amiloride-sensitive sodium channel, ENaC

2

Matriptase

2

Plasma kallikrein

2

Prostasin

2

Trypsin

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Chronic pancreatitis

2

Hepatic fibrosis

2

Hypertension

2

Multiple sclerosis

2

Postoperative reflux esophagitis

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

CHEBI

2

ChEMBL

2

DRUG BANK

2

EPA CompTox

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

BLOOD AND BLOOD FORMING ORGANS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIHEMORRHAGICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIFIBRINOLYTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Proteinase inhibitors

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

1

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

CAMOSTAT

0FD207WKDU

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Amiloride-sensitive sodium channel, ENaC

Plasma kallikrein

Conditions:

Multiple sclerosis

Chronic pancreatitis

Postoperative reflux esophagitis

Hepatic fibrosis

Camostat mesilate (FOY-305) is a synthetic f low-molecular weight protease inhibitor. It is able to inhibit trypsin, prostasin, matriptase and plasma kallikrein. In addition camostat attenuates airway epithelial sodium channel function and enhances m...

ucociliary clearance. Camostat mesilate tablets (FOIPAN®) are approved in Japan and used for the treatment of remission of acute symptoms of chronic pancreatitis and postoperative reflux esophagitis.

CAMOSTAT MESYLATE

451M50A1EQ

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Amiloride-sensitive sodium channel, ENaC

Plasma kallikrein

Conditions:

Multiple sclerosis

Chronic pancreatitis

Postoperative reflux esophagitis

Hepatic fibrosis

Camostat mesilate (FOY-305) is a synthetic f low-molecular weight protease inhibitor. It is able to inhibit trypsin, prostasin, matriptase and plasma kallikrein. In addition camostat attenuates airway epithelial sodium channel function and enhances m...

ucociliary clearance. Camostat mesilate tablets (FOIPAN®) are approved in Japan and used for the treatment of remission of acute symptoms of chronic pancreatitis and postoperative reflux esophagitis.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1